Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering has reported Revenue over the past 3 years, most recently at $455.0 for Q4 2022.

  • Quarterly results put Revenue at $455.0 for Q4 2022, down 99.76% from a year ago — trailing twelve months through Sep 2023 was $455.0 (down 99.91% YoY), and the annual figure for FY2022 was $316952.0, down 84.76%.
  • Revenue for Q4 2022 was $455.0 at Immuneering, down from $38380.0 in the prior quarter.
  • Over the last five years, Revenue for IMRX hit a ceiling of $748200.0 in Q1 2021 and a floor of $455.0 in Q4 2022.
  • Median Revenue over the past 3 years was $480835.0 (2020), compared with a mean of $384127.1.
  • Biggest five-year swings in Revenue: soared 37.27% in 2021 and later crashed 99.76% in 2022.
  • Immuneering's Revenue stood at $665080.0 in 2020, then plummeted by 71.49% to $189591.0 in 2021, then crashed by 99.76% to $455.0 in 2022.
  • The last three reported values for Revenue were $455.0 (Q4 2022), $38380.0 (Q3 2022), and $94419.0 (Q2 2022) per Business Quant data.